POTM: Scott Coward and Paul Kuznik Join Humacyte’s Board of Directors
Humacyte, a Durham, North Carolina-based biotechnology company, announced the appointment of Scott Coward and Paul Kuznik to its Board of Directors on September 28, 2026. These appointments coincide with Humacyte's commercial launch of Symvess and preparations for the launch of its acellular tissue engineered vessel (ATEV) for dialysis access. Coward brings expertise in corporate governance and legal affairs, while Kuznik contributes over three decades of experience in medical technology and cardiovascular devices.
Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note
Humacyte, Inc. (HUMA) shares fell 2.86% to $0.50, underperforming market gains. The stock has dropped 13.23% over the past month, while the broader Medical sector experienced a smaller decline. Upcoming earnings are projected to show a 35.71% EPS increase and 14.67% revenue growth year-over-year, despite a Zacks Rank of #4 (Sell).
Humacyte, Inc. - Common Stock (NQ: HUMA)
This article provides recent news headlines and financial updates for Humacyte, Inc. (NASDAQ: HUMA). It compiles news releases primarily from Benzinga and GlobeNewswire, detailing earnings previews and recaps, analyst ratings changes, financial results announcements, and updates on the company's Human Acellular Vessel™ (HAV™) technology and presentations at investor conferences. The content spans from August 2022 to August 2023.
Humacyte Director D. Scott Coward Files Form 3 Reporting No Beneficial Ownership
Humacyte Director D. Scott Coward filed a Form 3 Initial Statement of Beneficial Ownership with the SEC, indicating he holds no beneficial ownership in Humacyte, Inc. securities. This filing was triggered by his appointment as a director, with an event date of September 22, 2026, and was submitted on September 28, 2026. The document confirms that both non-derivative and derivative security tables are empty, affirming zero ownership as per SEC regulations.
Form 8K Humacyte Inc For: 28 September By Investing.com
This article reports on Humacyte Inc.'s Form 8K filing for September 28, 2026. The filing is a standard regulatory disclosure and the article provides the title of the filing. It also lists the company's stock symbol (HUMA) and its recent percentage change.
Two new directors join Humacyte (HUMA), one on the audit committee and one on the commercial committee.
Humacyte, Inc. (HUMA) has appointed Scott Coward and Paul Kuznik to its Board of Directors on September 22, 2026. Scott Coward, with a background in law and executive roles at Exact Sciences, will serve on the Audit Committee, while Paul Kuznik, a medical technology executive, will join the Commercial Committee. Both new directors will receive an annual cash retainer, committee service fees, and options to purchase 125,000 shares of common stock, with cash compensation prorated for 2026.
Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik
Humacyte (HUMA) has appointed Scott Coward and Paul Kuznik to its Board of Directors, bringing extensive experience in commercialization, enterprise leadership, and vascular healthcare. These appointments aim to strengthen the company's leadership as it expands its Symvess launch and prepares for the planned U.S. commercial launch of its acellular tissue engineered vessel (ATEV) for dialysis access. While the ATEV is approved for extremity vascular trauma, its use for dialysis access remains investigational and is not yet approved for sale by the FDA.
Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik
Humacyte, Inc. has announced the appointment of Scott Coward and Paul Kuznik to its Board of Directors, bringing extensive experience in commercialization, enterprise leadership, and global operations. These appointments aim to strengthen the company's leadership as it continues the Symvess launch and prepares for the commercial launch of its ATEV in the dialysis access indication. Coward and Kuznik will contribute to Humacyte's growth and strategy, particularly in preparation for the anticipated U.S. market launch in dialysis.
Humacyte, Inc. (HUMA) Stock Price, News, Quote & History
This article provides detailed financial information for Humacyte, Inc. (HUMA), including its current stock price, recent performance, key financial metrics, and analyst insights. It covers the company's business overview, performance against the S&P 500, earnings trends, and valuation measures. The content is sourced from Yahoo Finance, offering a comprehensive snapshot of HUMA's market position.
Humacyte Adds Scott Coward and Paul Kuznik to Board Ahead of Dialysis Launch
Humacyte Inc. (Nasdaq: HUMA) has appointed Scott Coward and Paul Kuznik to its board of directors, strengthening its commercialization, medical technology, and corporate governance expertise. These appointments come as the biotechnology company expands the launch of Symvess and prepares for the planned U.S. commercial launch of its bioengineered vessel for dialysis access. Coward brings experience in public-company leadership and corporate governance, while Kuznik contributes over three decades of experience in vascular medicine and cardiovascular device commercialization.
Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik
Humacyte, Inc. (Nasdaq: HUMA) has appointed Scott Coward and Paul Kuznik to its Board of Directors, enhancing its expertise in commercialization, enterprise leadership, and global operations. These additions are strategic as the company expands its Symvess® launch and prepares for the commercial launch of its ATEV in dialysis access. Both new board members bring extensive experience in the life sciences and medical technology sectors, which will be crucial for Humacyte's anticipated U.S. market launch in dialysis and its broader regenerative medicine initiatives.
Humacyte Inc (HUMA) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Humacyte Inc (HUMA) as of September 25, 2026, focusing on its volatility, financial, and investment risks. Key metrics include its Beta vs S&P 500 index, VaR, maximum drawdown, and various volatility and return figures over different periods. The data indicates significant volatility and downside risk for the stock.
Humacyte at H.C. Wainwright conference: dialysis push takes center stage By Investing.com
Humacyte (HUMA) presented its strategy at the H.C. Wainwright conference, focusing on its SYMVESS vessel platform. The company plans to expand from vascular trauma into dialysis access and coronary bypass, despite lower-than-expected Q2 sales of $0.4 million. Humacyte anticipates a supplemental BLA filing for dialysis access in November 2026, targeting a mid-2027 approval, and expects its current cash to fund operations into the second half of 2027.
Humacyte (NASDAQ: HUMA) director now holds 50,000 shares
Humacyte (NASDAQ: HUMA) director Keith Anthony Jones purchased 10,000 shares of common stock at $0.562 per share on September 14, 2026. Following this transaction, his direct holdings in the company increased to 50,000 shares. The purchase was an open-market transaction and not made under a Rule 10b5-1 trading plan.
Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Humacyte, Inc. announced that its Founder, President, and CEO, Laura Niklason, M.D., Ph.D., will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on September 16, 2026, in New York. The company, a commercial-stage biotechnology platform, develops universally implantable, bioengineered human tissues. Management will also be available for one-on-one meetings at the event.
Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Humacyte, Inc. announced that its Founder, President, and CEO, Laura Niklason, M.D., Ph.D., will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on September 16, 2026. The company, a commercial-stage biotechnology platform, focuses on developing universally implantable, bioengineered human tissues. Humacyte's Biologics License Application for its acellular tissue engineered vessel (ATEV) in vascular trauma was approved by the FDA in December 2024, and other ATEV applications are in late-stage clinical trials.
Humacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 Months
Humacyte, Inc. announced that the FDA has authorized an extension of the expiration dating period for its Symvess product from 18 months to 36 months when stored refrigerated. This extension, supported by additional stability data, aims to provide greater inventory flexibility for hospitals, simplify planning, and reduce product waste. Symvess is approved for urgent extremity arterial injury revascularization, and Humacyte plans to seek approval for dialysis access as a second indication.
Humacyte Inc (HUMA) (Q2 2026) Earnings Call Highlights: Strong Trial Results and Strategic ...
Humacyte Inc. (HUMA) reported significant positive interim results from its VO12 Phase III trial for dialysis access, demonstrating superior catheter-free days compared to standard care. The company is preparing for a supplemental BLA submission to the FDA in late 2026, aiming for a mid-2027 launch, while also advancing its coronary tissue-engineered vessel program and strengthening its commercial team. Despite slow initial commercial sales for vascular injury, the company anticipates improved uptake in the second half of 2026 and continues to manage substantial net losses.
Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions
Humacyte, Inc. announced its intention to file a supplemental Biologics License Application (BLA) with the FDA in November 2026 for its acellular tissue engineered vessel (ATEV) for dialysis access. This decision follows positive discussions with the FDA and is supported by data from three Phase 3 studies, including a V012 study showing ATEV outperformed standard care in women for dialysis access. The company aims to add dialysis access as the second approved indication for ATEV, following its prior approval for vascular trauma.
Humacyte (NASDAQ: HUMA) pulls redeemable warrants from Nasdaq
Humacyte, Inc. (HUMA) has voluntarily withdrawn its redeemable warrants from listing and registration on the Nasdaq Stock Market LLC. Each warrant was exercisable for one share of common stock at an exercise price of $11.50. The removal was executed under Section 12(b) of the Securities Exchange Act of 1934 and relevant CFR rules, with Nasdaq certifying compliance for the Form 25 filing.
Humacyte Plans November 2026 Supplemental BLA Submission for ATEV Dialysis Access Based on Phase 3 Data
Humacyte plans to submit a supplemental Biologics License Application (BLA) for its acellular tissue engineered vessel (ATEV) for dialysis access by November 2026. This submission follows positive Phase 3 study results, including the V012 study which showed ATEV provided women with three additional months without a dialysis catheter compared to the standard AV fistula. The company is confident in its regulatory path after discussions with the FDA, aiming to address unmet needs for dialysis patients.
Humacyte, Inc. (HUMA) Upgraded to Buy: Here's What You Should Know
Humacyte, Inc. (HUMA) has been upgraded to a Zacks Rank #2 (Buy), reflecting an upward trend in its earnings estimates. This upgrade suggests a positive outlook for the company's underlying business and its stock price due to the strong correlation between earnings estimate revisions and near-term stock movements. The Zacks Rank system, which categorizes stocks based on earnings estimate revisions, indicates that HUMA is now in the top 20% of Zacks-covered stocks, making it a strong candidate for market-beating returns.
Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA
Kahn Swick & Foti, LLC (KSF) is continuing its investigation into Humacyte, Inc. (HUMA) and its officers and directors following a securities class action lawsuit. The lawsuit stems from Humacyte's announcement in August 2024 that the FDA required more time to review its Biologic License Application and a subsequent FDA Form 483 in October 2024 detailing manufacturing violations. KSF's investigation focuses on potential breaches of fiduciary duties or violations of state or federal laws by Humacyte's leadership.
Investigation into Humacyte continues after FDA cites manufacturing violations and lawsuit proceeds.
Kahn Swick & Foti, LLC is investigating Humacyte, Inc. following an FDA inspection that found significant manufacturing violations, including issues with microbial quality assurance and testing. This led to a delay in the FDA's approval of Humacyte's Biologic License Application. Additionally, a securities class action lawsuit against the company is moving forward, alleging that Humacyte and its executives failed to disclose material information to investors.
Here's Why Humacyte, Inc. (HUMA) Fell More Than Broader Market
Humacyte, Inc. (HUMA) shares closed down 11.14% at $0.62, underperforming the broader market. The company's stock has also dropped 39.33% in the past month. Analysts anticipate Humacyte to report earnings of -$0.1 per share and revenue of $1.39 million in its upcoming earnings report, with full-year projections of -$0.34 per share and $8.03 million in revenue.
Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA
Kahn Swick & Foti, LLC (KSF) is continuing its investigation into Humacyte, Inc. (NasdaqGS: HUMA) and its officers and directors. This investigation follows a securities class action lawsuit filed against Humacyte after the FDA required additional time for its review of Humacyte's Biologic License Application and subsequently issued a Form 483 citing multiple violations at a manufacturing facility. KSF is examining whether fiduciary duties were breached or laws violated, and invites shareholders with relevant information to contact them.
Humacyte Stock (HUMA) Opinions on Phase 3 Trial Results
This article discusses investor opinions on the Phase 3 trial results for Humacyte (HUMA). The company announced positive results for its Human Acellular Vessel (HAV) in arteriovenous fistula (AVF) for hemodialysis, achieving superiority in primary endpoints compared to autogenous fistula. Investors are assessing the implications of these results for the company's future and stock performance.
Humacyte Stock (HUMA) Opinions on Phase 3 Trial Results
Discussions on Humacyte's Phase 3 trial outcomes for its vascular technology are driving notable stock gains, with observers pointing to accelerated buying. Insider activity shows both acquisitions and sales, contributing to varied commentary on the company's trajectory. Despite some mixed signals, the stock shows resilient performance amid broader biotech interest, leading to cautious optimism.
Humacyte publishes Phase 3 trial results in Lancet journal By Investing.com
Humacyte Inc. (NASDAQ: HUMA) announced the publication of one-year results from its V007 Phase 3 clinical trial in The Lancet Digital Health. The study demonstrated the superiority of Humacyte's acellular tissue engineered vessel (ATEV) over traditional arteriovenous fistula for hemodialysis access, especially for female patients and obese/diabetic male patients. The company previously reported positive two-year results from V007 and interim results from V012, and plans to submit a supplemental Biologics License Application for ATEV based on these findings.
A bioengineered vessel beat fistulas for women and men with obesity and diabetes on dialysis
Humacyte announced the publication of one-year results from its V007 Phase 3 trial in The Lancet Digital Health, showing superiority of its acellular tissue engineered vessel (ATEV) for hemodialysis access, especially in women and men with obesity and diabetes. This validation, along with positive V012 Phase 3 results, supports Humacyte's plan to submit a supplemental Biologics License Application (sBLA) in the second half of 2026 to expand the Symvess® label for a second AV access indication. The ATEV is currently FDA-approved only for extremity vascular trauma.
Humacyte Symvess: First Arizona Implant, 4 Cases | HUMA Stock News
Humacyte (Nasdaq: HUMA) announced that board-certified vascular surgeon Jeromy Brink, MD, performed the first four post-BLA-approval Symvess implants in Arizona within two weeks. Symvess is an FDA-approved off-the-shelf bioengineered blood vessel for urgent revascularization in extremity arterial injury when autologous vein grafts are not feasible. This development led to a moderate positive market reaction, with HUMA stock gaining 3.89%.
HC Wainwright Predicts Humacyte's Q3 Earnings (NASDAQ:HUMA)
HC Wainwright has revised its Q3 2026 EPS forecast for Humacyte (NASDAQ:HUMA) to a loss of $0.10 per share, down from $0.09, while maintaining a Buy rating and a $4.00 price target. The company recently reported a Q2 loss of $0.16 per share and revenue of $0.41 million, both missing consensus estimates. Despite a "Moderate Buy" consensus from analysts, shares are trading near their 52-week low, and some firms have lowered price targets or downgraded the stock.
Humacyte (NASDAQ:HUMA) Rating Lowered to Strong Sell at Wall Street Zen
Wall Street Zen downgraded Humacyte (NASDAQ:HUMA) to a "strong sell" rating, though the broader analyst consensus remains a "Moderate Buy" with a $6.11 price target. The company reported a quarterly loss of $0.16 per share, missing estimates by $0.05, and revenue of $0.41 million, falling short of the $1.04 million forecast. Despite a 10% rise, HUMA shares are trading near their 52-week low of $0.53, with institutional investors holding 44.71% and insiders 3.10% of the company.
Humacyte (HUMA) Stock Looks Stretched On Book Value Yet Reasonable After A 93% Fall
Humacyte stock has fallen 93.3% over the last five years, yet current valuations suggest it is still expensive, particularly based on its P/B ratio of 15.4x compared to the biotech industry average of 2.5x. This high valuation indicates that investors are placing a significant premium on its tissue engineered vessel platform and recent regulatory progress. The article concludes that the current stock price relies heavily on the success of its programs converting into commercial products on reasonable timelines, questioning whether this premium is justified by future outcomes.
Price to book forward of Humacyte, Inc. – NASDAQ:HUMAW
This article focuses on the "Price to book forward" financial metric for Humacyte, Inc., traded on NASDAQ under the symbol HUMAW. It provides a snapshot of this financial data point within the context of the company's financial overview on a trading platform. The content is primarily a data presentation with surrounding navigation and copyright information.
H.C. Wainwright Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $4
H.C. Wainwright has reiterated its Buy rating for Humacyte (HUMA.US), maintaining a price target of $4. This continued positive outlook from the analyst firm suggests confidence in the company's future performance.
Benchmark Lowers Humacyte (NASDAQ:HUMA) Price Target to $1.00
Benchmark has lowered its price target for Humacyte (NASDAQ:HUMA) to $1.00 from $2.00, while maintaining a "speculative buy" rating, implying a potential 51% upside. This adjustment comes after Humacyte missed Q2 earnings expectations, reporting a loss of $0.16 per share against an estimated $0.11 loss and revenue of $0.41 million below the $1.12 million estimate. Despite mixed analyst views, the consensus remains a "Moderate Buy" with an average target of $6.11, with potential catalysts including positive Phase 3 dialysis results and improved Symvess sales, though shareholder dilution and cash runway remain concerns.
Humacyte, Inc. Q2 2026: Revenue $406K, EPS $(0.16) — 10-Q Summary
Humacyte, Inc. reported its Q2 2026 financial results, showing $406K in revenue and a diluted EPS of $(0.16). The company achieved significant year-over-year revenue growth due to the commercial launch of Symvess and reduced its net loss. Humacyte is also progressing with clinical programs, planning an sBLA submission, and has reacquired worldwide commercialization control for its products.
Humacyte (HUMA) Reports Stronger Phase 3 Dialysis Results In Women
Humacyte (HUMA) announced stronger Phase 3 dialysis access data for its acellular tissue engineered vessel in female patients, outperforming the standard of care. The company plans to submit a supplemental Biologics License Application based on these results and has also received FDA acceptance for an Investigational New Drug application for a new coronary vessel candidate. This advancement highlights Humacyte's strategy to expand its bioengineered tissue platform beyond niche trauma uses into larger chronic indications like dialysis and coronary artery bypass graft.
Is Humacyte (HUMA) Undervalued Following Q2 2026 Earnings And Dialysis Trial Data?
Humacyte (HUMA) is in focus after its Q2 2026 earnings report, which showed modest revenue and a significant quarterly loss, compounded by a Nasdaq minimum bid price notice and interim Phase III dialysis trial data. Despite a fair value estimate of $4.00, suggesting it's 83.4% undervalued, the stock faces substantial execution risks, including high cash burn relative to revenue and an elevated P/B ratio compared to peers. The company's future hinges on the successful uptake of its dialysis and trauma treatments, aligning with optimistic analyst forecasts.
Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates
Humacyte, Inc. (HUMA) reported a Q2 loss of $0.16 per share, missing the Zacks Consensus Estimate of a $0.1 loss, and revenues of $0.41 million, falling short of estimates by 70.79%. The company's shares have dropped 26.1% year-to-date, and it currently holds a Zacks Rank #3 (Hold) with a mixed outlook from estimate revisions.
Humacyte Inc (HUMA) (Q2 2026) Earnings Call Highlights: Strong Trial Results and Strategic ...
Humacyte Inc. (HUMA) reported strong interim Phase III trial results for its ATEV in female dialysis patients, showing significant improvements over standard care. Despite low commercial sales in Q2 2026, the company is rebuilding its commercial team and preparing for a supplemental BLA submission for dialysis access. Humacyte is also advancing its coronary tissue-engineered vessel program and has secured DoD funding for vascular repair technology, indicating strategic progress despite ongoing net losses.
Humacyte Q2 Earnings Call Highlights
Humacyte reported Q2 commercial sales growth and outlined plans to expand adoption of its SYMVESS vascular repair product. The company also announced its intention to submit a supplemental biologics license application for dialysis access in the second half of 2026 and initiate a first-in-human coronary bypass study. Financial results showed a net loss of $36.8 million, an improvement from the prior year, with cash equivalents totaling $80.3 million.
Humacyte Q2 Earnings Call Highlights
Humacyte reported its Q2 earnings, highlighting commercial sales growth for its SYMVESS product and plans for a supplemental BLA submission for dialysis access. The company also detailed positive interim data from its V012 Phase III trial for dialysis patients and announced the initiation of a first-in-human coronary bypass study. Efforts are underway to expand SYMVESS adoption, rebuild its commercial team, and prepare for a potential dialysis access launch by Q2 2027.
Earnings call transcript: Humacyte misses Q2 2026 estimates as shares fall premarket
Humacyte missed analyst expectations for Q2 2026 revenue and EPS, causing its shares to fall over 10% in premarket trading. Despite the financial miss, the company highlighted progress in its commercial rebuild for SYMVESS, significant clinical trial results for its ATEV in dialysis access, and advancements in its CTEV coronary artery bypass grafting program. Management anticipates stronger adoption in the second half of 2026 and plans to file a supplemental Biologics License Application for dialysis access in November 2026.
Form 8K Humacyte Inc For: 12 August By Investing.com
This article from Investing.com announces that Humacyte Inc. has filed a Form 8K on August 12. The brief news item includes the company's stock symbol HUMA and notes its current price performance. No further details about the content of the Form 8K are provided.
Humacyte reports Q2 2026: Product revenue $0.4M, net loss $36.8M, cash $80.3M
Humacyte announced its second-quarter 2026 results, reporting product revenue of $0.4 million and a net loss of $36.8 million, with $80.3 million in cash. The company also shared positive interim Phase 3 results for its ATEV in female dialysis patients, planning a supplemental BLA submission in H2 2026, and received FDA acceptance for an IND for its CTEV, with a Phase 2a CABG study expected to start in Q3 2026.
Humacyte Inc (HUMA) Q2 2026 Earnings Report Preview: What To Expect
Humacyte Inc (HUMA) is scheduled to release its Q2 2026 earnings on August 12, 2026, with revenue expected at $1.12 million and an EPS of $-0.1. Analysts anticipate full-year 2026 revenue of $6.35 million and EPS of $-0.34. Despite previous revenue estimate declines, earnings estimates have shown an increase for both 2026 and 2027.
Humacyte, Inc. (NASDAQ:HUMA) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Eight brokerages have given Humacyte, Inc. (NASDAQ:HUMA) a consensus recommendation of "Moderate Buy," with one analyst issuing a sell rating and seven a buy rating. The average one-year price target is $6.25. Insider activity shows a sale by Shamik J. Parikh and a purchase by Director Kathleen Sebelius, while institutional investors like Geode Capital Management LLC and Marshall Wace LLP have significantly adjusted their holdings.
Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA
Kahn Swick & Foti, LLC (KSF) is continuing its investigation into Humacyte, Inc. regarding potential breaches of fiduciary duties by its officers and directors and violations of state or federal laws. This follows an FDA Form 483 inspection revealing violations at Humacyte's Durham facility and a securities class action lawsuit against the company, which recently had its motion to dismiss partially denied. KSF encourages long-term Humacyte shareholders with relevant information to contact them.
